Explore

Preventive Neurologist Highlights Overlooked Dementia Risk Factors: Vision and Hearing Loss

Preventive Neurologist Highlights Overlooked Dementia Risk Factors: Vision and Hearing Loss

Dr. Kellyann Niotis, a preventive neurologist and assistant professor of neurology at Weill Cornell Medicine, has identified vision and hearing loss as significant but often overlooked risk factors for cognitive decline, including dementia and Alzheimer's disease. During a public health campaign event, Brain Health Matters, Niotis emphasized the importance of regular sensory screenings as part of dementia prevention strategies. She referenced a 2024 Lancet study indicating that nearly half of all dementia cases worldwide could potentially be prevented by addressing risk factors such as sensory loss. Niotis explained that sensory loss might lead to social isolation, which is a known risk factor for cognitive decline. She also noted that sensory loss could reduce brain stimulation, which is crucial for maintaining brain health.

New MRI Metric PSMD Identifies Early Alzheimer's White Matter Damage

New MRI Metric PSMD Identifies Early Alzheimer's White Matter Damage

A recent study led by the Neuroimaging of Aging and Neurodegenerative Diseases research group at the Sant Pau Research Institute has introduced a new MRI metric, PSMD (peak width of skeletonized mean diffusivity), which detects early white matter abnormalities in Alzheimer's disease. Traditionally, Alzheimer's has been associated with gray matter damage, but this study highlights the impact on white matter as well. The research involved 496 participants, including those with sporadic Alzheimer's and individuals with Down syndrome, who are at a higher risk due to genetic factors. PSMD was found to identify microscopic changes in white matter tracts that are not visible on conventional MRI scans, providing a potential tool for early detection and monitoring of Alzheimer's progression.

Haptoglobin Types Linked to Cognitive Decline in Long COVID Patients

Haptoglobin Types Linked to Cognitive Decline in Long COVID Patients

A recent study has identified a link between inherited Haptoglobin phenotypes and cognitive decline in individuals with Long COVID. Researchers found that those with the Hp2-2 phenotype experienced significant cognitive dysfunction following physical exertion, unlike those with the Hp1-1 phenotype. The study also revealed differences in brain oxygen utilization and metabolic responses among the phenotypes. These findings suggest that Haptoglobin phenotyping could serve as a biomarker for identifying Long COVID patients at risk of cognitive decline, potentially guiding future precision medicine research.

Research Suggests Gut Microbiome Changes May Precede Alzheimer's Symptoms

Research Suggests Gut Microbiome Changes May Precede Alzheimer's Symptoms

A recent review published in the journal Nutrients highlights the potential link between gut microbiota changes and early Alzheimer's disease (AD) pathology. Researchers from Australia have summarized evidence suggesting that alterations in gut bacteria and their metabolites may occur before cognitive symptoms of AD appear. The review emphasizes the role of diet in influencing gut microbiota composition, which in turn may affect brain health and neuroinflammatory processes. While current treatments for AD offer limited benefits once cognitive decline is established, understanding these early biological changes could inform prevention strategies.

Study Links Artificial Sweeteners to Accelerated Memory Decline in Younger Adults

Study Links Artificial Sweeteners to Accelerated Memory Decline in Younger Adults

A recent study published by the American Academy of Neurology has found a significant correlation between the consumption of artificial sweeteners and accelerated cognitive decline, particularly in individuals under the age of 60. The study tracked 12,772 adults in Brazil over eight years, focusing on their intake of seven common sugar substitutes, including aspartame and saccharin. Results indicated that those with the highest consumption of these sweeteners experienced a 62% faster rate of cognitive decline compared to those with the lowest intake. The study highlights that while these sweeteners are often marketed as healthier alternatives to sugar, they may have unintended negative effects on brain health.

University of Florida's CDRC Targets Cancer Disparities in Underserved Communities

University of Florida's CDRC Targets Cancer Disparities in Underserved Communities

The University of Florida's Cancer Disparities Research Center (CDRC) is actively working to address cancer disparities in underserved communities, particularly among Black, Hispanic, and other minoritized groups. The CDRC, supported by the NCI-designated UF Health Cancer Institute, focuses on reducing cancer incidence and mortality rates in low-income areas in or near East Gainesville and rural Alachua County. The center employs community scientists to engage with diverse populations, recruiting participants for health disparities and cancer-related research. These community scientists are tasked with explaining research studies, obtaining informed consent, and collecting data from participants. The initiative is part of a broader effort to conduct community-based participatory research aimed at promoting cancer prevention, treatment, and survivorship.

Israeli Biological Therapy Shows Promise in Alzheimer's Treatment

Israeli Biological Therapy Shows Promise in Alzheimer's Treatment

An Israeli-developed biological therapy aimed at restoring the immune system's ability to protect the brain has demonstrated a favorable safety profile in its first human trial. The therapy, known as IBC-Ab002, is based on research by Professor Michal Schwartz from the Weizmann Institute of Science. Unlike most Alzheimer's treatments that target amyloid plaques, IBC-Ab002 focuses on restoring immune functions that decline with age. The trial involved 40 patients with early-stage Alzheimer's disease across medical centers in the UK, Israel, and the Netherlands. Results showed the treatment was safe and well-tolerated, with biological activity matching its design and reducing biomarkers associated with neuronal damage.

Researchers Identify Mitochondrial Plaques as New Alzheimer's Feature in Mice

Researchers Identify Mitochondrial Plaques as New Alzheimer's Feature in Mice

A recent study published in Nature Neuroscience has identified mitochondrial plaques (MPs) as a new pathological feature in Alzheimer's disease. Conducted by a team of biochemists, geneticists, and gerontologists, the research highlights the accumulation of MPs in the brains of genetically engineered mice and postmortem human brains with Alzheimer's. These plaques result from dysfunctional mitophagy, a process that fails to recycle damaged mitochondria. The study found that MPs can manifest alongside amyloid-beta aggregations, a known hallmark of Alzheimer's, and may directly affect neurons, making them a potential target for new treatments.

Study Links Early-Life Sugar Reduction to Lower Dementia Risk Decades Later

Study Links Early-Life Sugar Reduction to Lower Dementia Risk Decades Later

A recent study has found that reducing sugar intake during the first two years of life is associated with a lower risk of developing dementia later in life. Conducted by researchers at The Hong Kong University of Science and Technology, the study analyzed data from nearly 65,000 individuals born before and after World War II, a period when sugar rationing was implemented in the UK. The study found that those exposed to sugar rationing before birth and during their first two years had a significantly lower risk of dementia compared to those born after rationing ended. The findings suggest that early-life nutrition, particularly sugar intake, may have long-lasting effects on brain health and the onset of dementia.

Study Links Early Childhood Sugar Intake to Dementia Risk Reduction

Study Links Early Childhood Sugar Intake to Dementia Risk Reduction

Study Links Early Childhood Sugar Intake to Dementia Risk Reduction

Gut Microbiome Changes May Precede Alzheimer's Symptoms, Study Suggests

Gut Microbiome Changes May Precede Alzheimer's Symptoms, Study Suggests

A narrative review published in the journal Nutrients explores the potential link between gut microbiota, diet, and early Alzheimer's disease (AD) pathology. The review highlights that metabolic alterations and amyloid accumulation in the brain may be accompanied by changes in gut microbiota composition. These changes include disruptions in fermentation pathways and decreases in short-chain fatty acid (SCFA) biosynthesis. The review suggests that diet-induced microbiota changes could influence gut-brain communication, potentially impacting early AD pathology. However, the current evidence is limited, with most studies focusing on populations with AD or mild cognitive impairment rather than preclinical AD.

Glymphatic System's Role in Alzheimer's Disease Progression Explored

Glymphatic System's Role in Alzheimer's Disease Progression Explored

The glymphatic system, responsible for clearing metabolic waste from the brain, is increasingly recognized for its role in neurodegenerative diseases like Alzheimer's. A recent review highlights the use of diffusion tensor image analysis along the perivascular space (DTI-ALPS) to measure cerebrospinal fluid flow, which becomes impaired with age. This impairment is thought to contribute to the accumulation of protein aggregates, such as amyloid-beta, in the brain. The review suggests that reduced glymphatic drainage correlates with Alzheimer's progression, although methodological variability across studies presents challenges.